For research use only. Not for therapeutic Use.
PI-103(Cat No.:I003366)is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two critical enzymes in the PI3K/Akt/mTOR signaling pathway. By targeting both PI3K and mTOR, PI-103 disrupts processes such as cell proliferation, survival, and metabolism, making it valuable for cancer research. It is particularly effective in studying tumors with dysregulated PI3K signaling, including glioblastoma and other aggressive cancers. PI-103 is commonly used in preclinical studies to explore its therapeutic potential and to investigate resistance mechanisms to targeted cancer therapies.
Catalog Number | I003366 |
CAS Number | 371935-74-9 |
Synonyms | 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol |
Molecular Formula | C₁₉H₁₆N₄O₃ |
Purity | ≥95% |
Target | PI3K |
Solubility | DMSO ≥22mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
Storage | 3 years -20℃ powder |
IC50 | 2 nM/3 nM/3 nM/15 nM (p110α/β/δ/γ) |
IUPAC Name | 3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenol |
InChI | InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2 |
InChIKey | TUVCWJQQGGETHL-UHFFFAOYSA-N |
SMILES | C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O |
Reference | <p style=/line-height:25px/> <br>[4]. Bagci-Onder T, et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011 Jan 1;71(1):154-63. </p> |